Clinical trials: Oral Chemotherapy
Cancer
Evaluation of Patients' Satisfaction With the Dispensation of Their Oral Anticancer Treatment in Community Pharmacy
The pharmacist, as a specialist of medications, occupies a strategic position: he participates in a global care of their patients.
- Trial name
- ORCA (NCT03275675)
- Testing
- Oral anticancer medications
- Where
- France
- Volunteers
- 104 people
- Sponsor
- University Hospital, Clermont-Ferrand
HIV Infections, Pregnancy
A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
The purpose of this study is to see if giving nelfinavir (NFV) plus zidovudine (ZDV) plus lamivudine (3TC) to HIV-positive pregnant women and their babies is safe.
- Trial name
- NCT00000887
- Testing
- Nelfinavir mesylate, Lamivudine, Zidovudine
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Castration-Resistant Prostate Cancer
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
- Trial name
- AFFIRM (NCT00974311)
- Testing
- Enzalutamide
- Where
- 249 sites in United States, Argentina and 13 more
- Volunteers
- 1,199 people
- Sponsor
- Pfizer
Post Herpetic Neuralgia, Pain
A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
This study is a 3-part, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamic properties of iN1011-N17 after Oral Administration in Healthy…
- Conditions
- Post Herpetic Neuralgia, Pain, Osteoarthritis, Neuropathic Pain
- Trial name
- NCT06218784
- Testing
- iN1011-N17 HCl Suspension (Part 1), iN1011-N17 HCl Capsule (Part 1), iN1011-N17 HCl Capsule (Part 2)
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- iN Therapeutics Co., Ltd.
Hepatocellular Carcinoma, Liver Cancer
Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma
Capecitabine is a chemotherapeutic that has been approved for use in breast and colorectal cancers. The advantages of capecitabine are that (1) it is an oral drug; and (2) it is less toxic than many other chemotherapeutics.
- Trial name
- NCT00076609
- Testing
- PHY906, capecitabine
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 31 people
- Sponsor
- PhytoCeutica
Non Small Cell Lung Cancer
Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC
This is a prospective, randomized, multicenter real-world study, which aims to investigate the efficacy and safety of Jinfukang oral liquid combined with chemotherapy as first-line treatment regimen for patients with…
- Trial name
- NCT05098990
- Testing
- Jinfukang oral liquid, Platinum-based doublet chemotherapy
- Volunteers
- 328 people
- Sponsor
- China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
This is a single center 2-phase study to assess effects of using text messages on adherence to oral chemotherapy for patients with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma.
- Trial name
- NCT06446661
- Testing
- High Intensity, No Text Messagings, Low Intensity Text Messaging
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Chicago
Diabetes, Diabetes Mellitus, Type 2
Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
This trial is conducted in Asia. This is a clinical trial investigating the effectiveness of using Biphasic Insulin Aspart 70/30 in two different treatment regiments for 6 months in subjects with type 2 diabetes, not well…
- Trial name
- NCT00184561
- Testing
- biphasic insulin aspart
- Where
- 8 sites in China
- Volunteers
- 321 people
- Sponsor
- Novo Nordisk A/S
Carcinoma, Non-Small-Cell Lung
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with…
- Trial name
- NCT00805194
- Testing
- BIBF 1120 plus docetaxel
- Where
- 210 sites in Austria, Belarus and 25 more
- Volunteers
- 1,314 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
The purpose of this study is to determine the efficacy and safety of TAK-875 (fasiglifam), once daily (QD), in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01456195
- Testing
- Fasiglifam
- Where
- 95 sites in United States, Argentina and 6 more
- Volunteers
- 421 people
- Sponsor
- Takeda
Breast Cancer
An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)
The primary objective of this study is to evaluate the time to progression. Secondary objectives are safety, OS and pharmacogenetic analysis. Sixty patients will be enrolled into this study.
- Trial name
- NCT00589901
- Testing
- capecitabine and cyclophosphamide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial
Non Small Cell Lung Cancer (NSCLC) represents the first cancer related cause of death worldwide with 1.4 millions of deaths every years.
- Trial name
- ONC-MANILA12 (NCT02176369)
- Testing
- Vinorelbine
- Where
- 20 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Mucositis, Nephrotoxicity
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients.
- Conditions
- Mucositis, Nephrotoxicity, Ototoxicity
- Trial name
- NCT03480971
- Testing
- Tempol
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Matrix Biomed, Inc.
Rectal Cancer
Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
The study is designed to test the hypothesis that patients with Locally advanced rectal cancer ( LARC) treated with Total neoadjuvant therapy (TNT) and Total mesorectal excision (TME) or Non-operative management (NOM) will have…
- Trial name
- NCT02008656
- Testing
- Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin
- Where
- 26 sites in United States
- Volunteers
- 358 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Healthy Volunteers
TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin
The purpose of this study is to evaluate the effect of multiple oral doses of clarithromycin on the pharmacokinetics of TAK-438 and its metabolites in healthy male adult participants following a single oral dose of TAK-438.
- Trial name
- NCT02774902
- Testing
- TAK-438, Clarithromycin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Takeda
Non-small Cell Lung Cancer
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
The purpose of this study is to compare the anti-tumor efficacy of oral single-agent rociletinib, as measured by investigator assessment of the PFS, with that of single-agent cytotoxic chemotherapy in patients with EGFR-mutated…
- Trial name
- NCT02322281
- Testing
- Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel
- Where
- 80 sites in United States, Australia and 8 more
- Volunteers
- 149 people
- Sponsor
- Clovis Oncology, Inc.
Germ Cell Tumor, Non-seminomatous Germ Cell Tumor
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
This is an open label randomized phase II trial of maintenance oral etoposide vs. observation in patinets with relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).
- Conditions
- Germ Cell Tumor, Non-seminomatous Germ Cell Tumor, Ovarian Germ Cell Tumor
- Trial name
- NCT04804007
- Testing
- Etoposide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Nabil Adra
Stomatitis
Laser for Oral Mucositis in Pediatric Onco-hematology
Children with cancer undergoing intensive chemotherapy (CT) regimens experience many side effects among which oral mucositis (OM) is one of the most debilitating.
- Trial name
- LAMPO (NCT02762019)
- Testing
- Laser therapy
- Where
- 8 sites in Italy
- Volunteers
- 101 people
- Sponsor
- IRCCS Burlo Garofolo
Carcinoma of Unknown Primary, Head and Neck Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002507
- Testing
- mitomycin C, porfiromycin, brachytherapy
- Where
- United States
- Sponsor
- Yale University
Metastatic Breast Cancer
BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer
This is a prospective, multi-center, open-label, single arm, phase II study with a 2-stage design and Bayesian interim monitoring to investigate the safety and efficacy of BEZ235 in patients with progressive metastatic HR+ HER2…
- Trial name
- NCT01288092
- Testing
- BEZ235
- Sponsor
- Novartis Pharmaceuticals